サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1684132

ポイントオブケアにおける分子診断市場：用途別、技術別、場所別、製品別、国別 - エグゼクティブコンサルタントガイドおよび分析付き（2025年～2029年）

Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Analysis 2025 - 2029

出版日
ページ情報
英文 511 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ポイントオブケアにおける分子診断市場：用途別、技術別、場所別、製品別、国別 - エグゼクティブコンサルタントガイドおよび分析付き（2025年～2029年）
出版日: 2025年03月20日
発行: Howe Sound Research
ページ情報: 英文 511 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ポイントオブケア検査は市場でその存在感を示しています。各社は驚くべき成長を報告しています。コストの削減、治療成績の向上、さらには抗微生物剤耐性との戦いにも役立っています。

当レポートは、世界のポイントオブケアにおける分子診断市場について調査し、市場の概要とともに、用途別、技術別、場所別、製品別、国別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

第3章 計測、自動化、診断の動向

  • 計測と自動化

第4章 業界の概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 計測機器サプライヤー
    • 薬品・試薬メーカー
    • 病理サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室
    • 監査機関
    • 認証機関
  • 臨床検査市場のセグメント
  • 業界構造

第5章 主要企業のプロファイル

  • Abbott Laboratories
  • Abionic
  • Accelerate Diagnostics
  • Access Bio
  • Ador Diagnostics
  • ADT Biotech
  • Akonni Biosystems
  • Alveo Technologies
  • Anitoa
  • Applied BioCode
  • Aureum Diagnostics
  • Aus Diagnostics
  • Autonomous Medical Devices
  • Baebies
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • Binx Health
  • Biocartis
  • BioFire Diagnostics（bioMerieux）
  • bioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc
  • Bosch Healthcare Solutions GmbH
  • Cepheid（Danaher）
  • Credo Diagnostics Biomedical
  • Cue Health
  • Curetis（OpGen）
  • Detect
  • Diagenode Diagnostics（Hologic）
  • Diasorin S.p.A.
  • DNAe
  • Domus Diagnostics
  • Enzo Biochem
  • Eurofins Scientific
  • Fluxergy
  • Fusion Genomics.
  • Genedrive
  • Genetic Signatures
  • GenMark Dx（Roche）
  • Genomadix
  • Getlabs
  • Global Access Diagnostics
  • Grip Molecular Technologies
  • Hologic
  • Immunexpress
  • Inflammatix
  • Invetech
  • Iollo
  • J&J Innovative Medicine
  • Karius
  • Lucira Health（Pfizer）
  • LumiraDx
  • Maxim Biomedical
  • Meep
  • Meridian Bioscience
  • Millipore Sigma
  • Molbio Diagnostics
  • NanoDx
  • Nanomix
  • Novacyt
  • Novel Microdevices
  • Novus Diagnostics
  • Nuclein
  • OnsiteGene
  • Operon
  • OraSure Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Prenetics
  • Primerdesign（Novacyt）
  • Prominex
  • Proof Diagnostics
  • Qiagen
  • QuantuMDx
  • QuidelOrtho
  • R-Biopharm AG
  • Response Biomedical
  • Revvity
  • Roche Diagnostics
  • Salignostics
  • SD Biosensor
  • Seegene
  • Sekisui Diagnostics
  • Siemens Healthineers
  • Sona Nanotech
  • SpeeDx
  • T2 Biosystems
  • Talis Biomedical
  • Thermo Fisher Scientific
  • Uniogen
  • Veramarx
  • Veredus Laboratories
  • XCR Diagnostics
  • Zhejiang Orient Gene Biotech

第6章 市場動向

  • 成長促進要因
  • 成長阻害要因

第7章 分子診断- 感染症の最近の動向

第8章 世界のポイントオブケアにおける分子診断市場

  • 国別世界市場概要
  • 用途別世界市場- 概要
  • 技術別世界市場- 概要
  • 場所別世界市場- 概要
  • 製品別世界市場- 概要

第9章 世界のポイントオブケアにおける分子診断市場：用途別

  • 呼吸器感染症
  • 消化器感染症
  • 性感染症
  • その他

第10章 世界のポイントオブケアにおける分子診断市場：技術別

  • PCR
  • NGS/プローブ
  • その他

第11章 世界のポイントオブケアにおける分子診断市場：場所別

  • 病院
  • クリニック・診療所
  • 高齢者施設
  • その他

第12章 世界のポイントオブケアにおける分子診断市場：製品別

  • 機器
  • カートリッジ
  • その他

第13章 付録

図表

Table of Tables

  • Table 1: Seven Key Diagnostic Laboratory Technology Trends
  • Table 2: Market Players by Type
  • Table 3: Clinical Laboratory Departments and Segments
  • Table 4: Laboratory Management Focus - Different Approaches
  • Table 5: Key Segmentation Variables Going Forward
  • Table 6: Five Factors Driving Growth
  • Table 7: Four Factors Limiting Growth
  • Table 8: Global Market by Region
  • Table 9: Global Market by Application
  • Table 10: Global Market by Technology
  • Table 11: Global Market by Place
  • Table 12: Global Market by Product
  • Table 13: Respiratory Infectious Disease by Country
  • Table 14: Gastrointestinal Infectious Disease by Country
  • Table 15: Sexually Transmitted Disease by Country
  • Table 16: Other Application by Country
  • Table 17: PCR by Country
  • Table 18: NGS/Probe by Country
  • Table 19: Other Technology by Country
  • Table 20: Hospital Point of Care by Country
  • Table 21: Clinic or Physician Office Lab by Country
  • Table 22: Seniors Facility by Country
  • Table 23: Other Place by Country
  • Table 24: Instrument by Country
  • Table 25: Cartridge by Country
  • Table 26: Other Product by Country
  • Table 27: The Most Common Assays
  • Table 28: Largest Revenue Assays
  • Table 29: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Global Healthcare Spending
  • Figure 2: Centralized vs. Decentralized Laboratory Service
  • Figure 3: A Highly Multiplexed Syndromic Testing Unit
  • Figure 4: The Real Cost to Sequence the Human Genome
  • Figure 5: The Codevelopment Process
  • Figure 6: The Road to Diagnostics
  • Figure 7: Percentage of World Population Over 65
  • Figure 8: Chart Infectious Disease Decline
  • Figure 9: Global Market Shares Chart
  • Figure 10: Global Market by Application - Base vs. Final
  • Figure 11: Global Market by Application Base Year
  • Figure 12: Global Market by Application End Year
  • Figure 13: Application Share by Year
  • Figure 14: Application Segments Growth
  • Figure 15: Global Market by Technology - Base vs. Final
  • Figure 16: Global Market by Technology Base Year
  • Figure 17: Global Market by Technology End Year
  • Figure 18: Technology Share by Year
  • Figure 19: Technology Segments Growth
  • Figure 20: Global Market by Place - Base vs. Final
  • Figure 21: Global Market by Place Base Year
  • Figure 22: Global Market by Place End Year
  • Figure 23: Place Share by Year
  • Figure 24: Place Segments Growth
  • Figure 25: Global Market by Product - Base vs. Final
  • Figure 26: Global Market by Product Base Year
  • Figure 27: Global Market by Product End Year
  • Figure 28: Product Share by Year
  • Figure 29: Product Segments Growth
  • Figure 30: Respiratory Infectious Disease Diagnostics Growth
  • Figure 31: Gastrointestinal Infectious Disease Growth
  • Figure 32: Sexually Transmitted Disease Growth
  • Figure 33: Other Application Growth
  • Figure 34: PCR Growth
  • Figure 35: NGS/Probe Growth
  • Figure 36: Other Technology Growth
  • Figure 37: Hospital Point of Care Growth
  • Figure 38: Clinic or Physician Office Lab Growth
  • Figure 39: Seniors Facility Growth
  • Figure 40: Other Place Growth
  • Figure 41: Instrument Growth
  • Figure 42: Cartridge Growth
  • Figure 43: Other Product Growth
  • Figure 44: IVD Test Menu Growth
  • Figure 45: IVD Test Average Fees - A Ten Year View
目次

OVERVIEW:

Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.

Point of Care testing is proving itself in the market. Players are reporting surprising growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out for five years.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

  • 1.1. Strategic Situation Analysis
  • 1.2. Guide for Executives, Marketing and Business Development Staff
  • 1.3. Guide for Management Consultants and Investment Advisors

2. Introduction and Market Definition

  • 2.1. What are Molecular Diagnostics at the Point of Care?
  • 2.2. The Diagnostics Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenues
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare Spending
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Healthcare and Pharmaceuticals
    • 2.5.3. Spending on Diagnostics
    • 2.5.4. Important Role of Insurance for Medical Services

3. Instrumentation, Automation and Diagnostic Trends

  • 3.1. Instrumentation and Automation
    • 3.1.1. Traditional Automation and Centralization
    • 3.1.2. The New Automation, Decentralization and Point Of Care
    • 3.1.3. Instruments Key to Market Share
    • 3.1.4. Bioinformatics Plays a Role
    • 3.1.5. PCR Takes Command
    • 3.1.6. Next Generation Sequencing Fuels a Revolution
    • 3.1.7. NGS Impact on Pricing
    • 3.1.8. Whole Genome Sequencing, A Brave New World
    • 3.1.9. Companion Diagnostics Blurs Diagnosis and Treatment

4. Industry Overview

  • 4.1. Players in a Dynamic Market
    • 4.1.1. Academic Research Lab
    • 4.1.2. Diagnostic Test Developer
    • 4.1.3. Instrumentation Supplier
    • 4.1.4. Chemical/Reagent Supplier
    • 4.1.5. Pathology Supplier
    • 4.1.6. Independent Clinical Laboratory
    • 4.1.7. Public National/regional Laboratory
    • 4.1.8. Hospital Laboratory
    • 4.1.9. Physicians Office Lab (POLS)
    • 4.1.10. Audit Body
    • 4.1.11. Certification Body
  • 4.2. The Clinical Laboratory Market Segments
    • 4.2.1. Traditional Market Segmentation
    • 4.2.2. Laboratory Focus and Segmentation
  • 4.3. Industry Structure
    • 4.3.1. Hospital Testing Share
    • 4.3.2. Economies of Scale
      • 4.3.2.1. Hospital vs. Central Lab
    • 4.3.3. Physician Office Lab's
    • 4.3.4. Physician's and POCT

5. Profiles of Key MDx Companies

  • 5.1. Abbott Laboratories
  • 5.2. Abionic
  • 5.3. Accelerate Diagnostics
  • 5.4. Access Bio
  • 5.5. Ador Diagnostics
  • 5.6. ADT Biotech
  • 5.7. Akonni Biosystems
  • 5.8. Alveo Technologies
  • 5.9. Anitoa
  • 5.10. Applied BioCode
  • 5.11. Aureum Diagnostics
  • 5.12. Aus Diagnostics
  • 5.13. Autonomous Medical Devices
  • 5.14. Baebies
  • 5.15. Beckman Coulter Diagnostics (Danaher)
  • 5.16. Becton, Dickinson and Company
  • 5.17. Binx Health
  • 5.18. Biocartis
  • 5.19. BioFire Diagnostics (bioMerieux)
  • 5.20. bioMerieux Diagnostics
  • 5.21. Bio-Rad Laboratories, Inc
  • 5.22. Bosch Healthcare Solutions GmbH
  • 5.23. Cepheid (Danaher)
  • 5.24. Credo Diagnostics Biomedical
  • 5.25. Cue Health
  • 5.26. Curetis (OpGen)
  • 5.27. Detect
  • 5.28. Diagenode Diagnostics (Hologic)
  • 5.29. Diasorin S.p.A.
  • 5.30. DNAe
  • 5.31. Domus Diagnostics
  • 5.32. Enzo Biochem
  • 5.33. Eurofins Scientific
  • 5.34. Fluxergy
  • 5.35. Fusion Genomics.
  • 5.36. Genedrive
  • 5.37. Genetic Signatures
  • 5.38. GenMark Dx (Roche)
  • 5.39. Genomadix
  • 5.40. Getlabs
  • 5.41. Global Access Diagnostics
  • 5.42. Grip Molecular Technologies
  • 5.43. Hologic
  • 5.44. Immunexpress
  • 5.45. Inflammatix
  • 5.46. Invetech
  • 5.47. Iollo
  • 5.48. J&J Innovative Medicine
  • 5.49. Karius
  • 5.50. Lucira Health (Pfizer)
  • 5.51. LumiraDx
  • 5.52. Maxim Biomedical
  • 5.53. Meep
  • 5.54. Meridian Bioscience
  • 5.55. Millipore Sigma
  • 5.56. Molbio Diagnostics
  • 5.57. NanoDx
  • 5.58. Nanomix
  • 5.59. Novacyt
  • 5.60. Novel Microdevices
  • 5.61. Novus Diagnostics
  • 5.62. Nuclein
  • 5.63. OnsiteGene
  • 5.64. Operon
  • 5.65. OraSure Technologies
  • 5.66. Oxford Nanopore Technologies
  • 5.67. Panagene
  • 5.68. Prenetics
  • 5.69. Primerdesign (Novacyt)
  • 5.70. Prominex
  • 5.71. Proof Diagnostics
  • 5.72. Qiagen
  • 5.73. QuantuMDx
  • 5.74. QuidelOrtho
  • 5.75. R-Biopharm AG
  • 5.76. Response Biomedical
  • 5.77. Revvity
  • 5.78. Roche Diagnostics
  • 5.79. Salignostics
  • 5.80. SD Biosensor
  • 5.81. Seegene
  • 5.82. Sekisui Diagnostics
  • 5.83. Siemens Healthineers
  • 5.84. Sona Nanotech
  • 5.85. SpeeDx
  • 5.86. T2 Biosystems
  • 5.87. Talis Biomedical
  • 5.88. Thermo Fisher Scientific
  • 5.89. Uniogen
  • 5.90. Veramarx
  • 5.91. Veredus Laboratories
  • 5.92. XCR Diagnostics
  • 5.93. Zhejiang Orient Gene Biotech

6. Market Trends

  • 6.1. Factors Driving Growth
    • 6.1.1. New Genotypes Creating New Markets
    • 6.1.2. Aging Population a Boon for All Diagnostics
    • 6.1.3. Developing World Driving ID Dx Growth
    • 6.1.4. Point of Care - Why Centralization is Losing Steam
    • 6.1.5. Self Testing
    • 6.1.6. The Need for Speed
  • 6.2. Factors Limiting Growth
    • 6.2.1. Lower Costs
    • 6.2.2. Infectious Disease is Declining
    • 6.2.3. Wellness Hurts
    • 6.2.4. Economic Growth improves Living Standards

7. Molecular Dx - Infectious Disease Recent Developments

  • 7.1. Recent Developments - Importance and How to Use This Section
    • 7.1.1. Importance of These Developments
    • 7.1.2. How to Use This Section
  • 7.2. Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform
  • 7.3. Roche receives FDA clearance for STI at POC
  • 7.4. Smartphone-Enabled Platform Transforms POC Testing
  • 7.5. Credo Preps MDx System, Multiplex Respiratory Test for US Launch
  • 7.6. A low-cost CRISPR-based paper strip test for flu
  • 7.7. AMDI Receives Award to Develop 10 Minute POC Respiratory Panel
  • 7.8. Roche to Acquire LumiraDx Point-of-Care Testing Tech
  • 7.9. DiaSorin to Deliver Updated Instruments, New Assays in 2024/25
  • 7.10. ReadyGo Diagnostics, Gemina Labs Expand MDx Pact
  • 7.11. DiagMetrics Developing Breath Assays
  • 7.12. Fortis Life Sciences Acquires IPOC
  • 7.13. Domus Diagnostics Wins NIH RADx Tech Contract
  • 7.14. Llusern Scientific to Launch POC MDx UTI Panel
  • 7.15. Altratech Enters POC MDx Testing Space with Unique Tech
  • 7.16. BioMerieux SpotFire MDx POC System Leverages Novel Approach
  • 7.17. Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System
  • 7.18. LEX Diagnostics Developing Ultra-Fast Low-Cost PCR
  • 7.19. Sherlock Biosciences Adds to Infectious Disease Dx Toolkit
  • 7.20. NanoDx Prepares for Point-of-Care Commercialization
  • 7.21. Paragraf to Study New POC Test to Guide Antibiotic Selection
  • 7.22. MicroGEM to Expand 30-Minute RT-PCR System
  • 7.23. Startup Detect to Roll Out Next-Gen Molecular Instrument
  • 7.24. Diagnostics for the Real World Third-Generation POC Platform
  • 7.25. Salignostics Closes Funding Round
  • 7.26. Cue Health Targets DTC Market in 2022
  • 7.27. Grip Molecular Developing Home Respiratory Panel
  • 7.28. Mainz Biomed Developing Home ColoAlert Assay
  • 7.29. MFB Fertility Closes Series A Financing Round
  • 7.30. Home Test Company Prenetics to go Public
  • 7.31. Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
  • 7.32. BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
  • 7.33. Talis Biomedical Discusses Point-of-Care
  • 7.34. Roche to Acquire GenMark Diagnostics for $1.8B
  • 7.35. Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 7.36. Hologic to Acquire Mobidiag
  • 7.37. Lucira Health Focuses on User Friendly Approach to Home Testing
  • 7.38. Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
  • 7.39. Fluidigm Plans 'Durable' Diagnostics, Clinical Business
  • 7.40. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
  • 7.41. Mammoth Biosciences Developing Pathogen Detection Tech
  • 7.42. Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
  • 7.43. Scanogen Developing 90 Minute Infection Test
  • 7.44. Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
  • 7.45. FDA Provides Self Testing SARS-CoV-2 EAU Guidance
  • 7.46. Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
  • 7.47. Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
  • 7.48. Qiagen Respiratory Panel with Coronavirus Receives CE Mark
  • 7.49. Lumos Diagnostics Closes $15M Series A Funding

8. The Global Market for Molecular Diagnostics at the Point of Care

  • 8.1. Global Market Overview by Country
    • 8.1.1. Table - Global Market by Country
    • 8.1.2. Chart - Global Market by Country
  • 8.2. Global Market by Application - Overview
    • 8.2.1. Table - Global Market by Application
    • 8.2.2. Chart - Global Market by Application - Base/Final Year Comparison
    • 8.2.3. Chart - Global Market by Application - Base Year
    • 8.2.4. Chart - Global Market by Application - End Year
    • 8.2.5. Chart - Global Market by Application - Share by Year
    • 8.2.6. Chart - Global Market by Application - Segments Growth
  • 8.3. Global Market by Technology - Overview
    • 8.3.1. Table - Global Market by Technology
    • 8.3.2. Chart - Global Market by Technology - Base/Final Year Comparison
    • 8.3.3. Chart - Global Market by Technology - Base Year
    • 8.3.4. Chart - Global Market by Technology - End Year
    • 8.3.5. Chart - Global Market by Technology - Share by Year
    • 8.3.6. Chart - Global Market by Technology - Segments Growth
  • 8.4. Global Market by Place - Overview
    • 8.4.1. Table - Global Market by Place
    • 8.4.2. Chart - Global Market by Place - Base/Final Year Comparison
    • 8.4.3. Chart - Global Market by Place - Base Year
    • 8.4.4. Chart - Global Market by Place - End Year
    • 8.4.5. Chart - Global Market by Place - Share by Year
    • 8.4.6. Chart - Global Market by Place - Segments Growth
  • 8.5. Global Market by Product - Overview
    • 8.5.1. Table - Global Market by Product
    • 8.5.2. Chart - Global Market by Product - Base/Final Year Comparison
    • 8.5.3. Chart - Global Market by Product - Base Year
    • 8.5.4. Chart - Global Market by Product - End Year
    • 8.5.5. Chart - Global Market by Product - Share by Year
    • 8.5.6. Chart - Global Market by Product - Segments Growth

9. Global MDx at the Point of Care Markets - By Application

  • 9.1. Respiratory Infectious Disease
    • 9.1.1. Table Respiratory Infectious Disease - by Country
    • 9.1.2. Chart - Respiratory Infectious Disease Growth
  • 9.2. Gastrointestinal Infectious Disease
    • 9.2.1. Table Gastrointestinal Infectious Disease - by Country
    • 9.2.2. Chart - Gastrointestinal Infectious Disease Growth
  • 9.3. Sexually Transmitted Disease
    • 9.3.1. Table Sexually Transmitted Disease - by Country
    • 9.3.2. Chart - Sexually Transmitted Disease Growth
  • 9.4. Other Application
    • 9.4.1. Table Other Application - by Country
    • 9.4.2. Chart - Other Application Growth

10. Global MDx Markets at the Point of Care - by Technology

  • 10.1. PCR
    • 10.1.1. Table PCR - by Country
    • 10.1.2. Chart - PCR Growth
  • 10.2. NGS/Probe
    • 10.2.1. Table NGS/Probe - by Country
    • 10.2.2. Chart - NGS/Probe Growth
  • 10.3. Other Technology
    • 10.3.1. Table Other Technology - by Country
    • 10.3.2. Chart - Other Technology Growth

11. Global MDx at the Point of Care Markets - by Place

  • 11.1. Hospital Point of Care
    • 11.1.1. Table Hospital Point of Care - by Country
    • 11.1.2. Chart - Hospital Point of Care Growth
  • 11.2. Clinic or Physician Office Lab
    • 11.2.1. Table Clinic or Physician Office Lab - by Country
    • 11.2.2. Chart - Clinic or Physician Office Lab Growth
  • 11.3. Seniors Facility
    • 11.3.1. Table Seniors Facility - by Country
    • 11.3.2. Chart - Seniors Facility Growth
  • 11.4. Other Place
    • 11.4.1. Table Other Place- by Country
    • 11.4.2. Chart - Other Place Growth

12. Global MDx at the Point of Care Markets - by Product

  • 12.1. Instrument
    • 12.1.1. Table Instrument - by Country
    • 12.1.2. Chart - Instrument Growth
  • 12.2. Cartridge
    • 12.2.1. Table Cartridge - by Country
    • 12.2.2. Chart - Cartridge Growth
  • 12.3. Other Product
    • 12.3.1. Table Other Product - by Country
    • 12.3.2. Chart - Other Product Growth

13. Appendices

  • 13.1. Growth of Approved IVD Test Menu
  • 13.2. Growth of Approved Average IVD Test Fee
  • 13.3. The Most Used IVD Assays
  • 13.4. The Highest Grossing Assays
  • 13.5. Laboratory Fees Schedule